BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 17105651)

  • 1. Multiple endocrine neoplasia type 2.
    Marini F; Falchetti A; Del Monte F; Carbonell Sala S; Tognarini I; Luzi E; Brandi ML
    Orphanet J Rare Dis; 2006 Nov; 1():45. PubMed ID: 17105651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic testing in endocrinology: lessons learned from experience with multiple endocrine neoplasia type 2 (MEN2).
    Jimenez C; Gagel RF
    Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S150-7. PubMed ID: 15135800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2.
    Moore SW; Appfelstaedt J; Zaahl MG
    J Pediatr Surg; 2007 Feb; 42(2):326-32. PubMed ID: 17270543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic testing in multiple endocrine neoplasia and related syndromes.
    Calender A
    Forum (Genova); 1998; 8(2):146-59. PubMed ID: 9666051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma.
    Krampitz GW; Norton JA
    Cancer; 2014 Jul; 120(13):1920-31. PubMed ID: 24699901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation.
    Frank-Raue K; Raue F
    Recent Results Cancer Res; 2015; 204():139-56. PubMed ID: 26494387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple endocrine neoplasia, the old and the new: a mini review.
    Pasquali D; Di Matteo FM; Renzullo A; Accardo G; Esposito D; Barbato F; Colantuoni V; Circelli L; Conzo G
    G Chir; 2012; 33(11-12):370-3. PubMed ID: 23140918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of patients with hereditary medullary thyroid carcinoma.
    Fitze G
    Eur J Pediatr Surg; 2004 Dec; 14(6):375-83. PubMed ID: 15630638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular advances in medullary thyroid cancer diagnostics.
    Hubner RA; Houlston RS
    Clin Chim Acta; 2006 Aug; 370(1-2):2-8. PubMed ID: 16519882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple endocrine neoplasia type 2.
    Lodish M
    Front Horm Res; 2013; 41():16-29. PubMed ID: 23652668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Multiple endocrine neoplasia: genetic aspects].
    Calender A;
    Bull Acad Natl Med; 2010 Jan; 194(1):81-95; discussion 95-6. PubMed ID: 20669561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey.
    Aydoğan Bİ; Yüksel B; Tuna MM; Navdar Başaran M; Akkurt Kocaeli A; Ertörer ME; Aydın K; Güldiken S; Şimşek Y; Cihan Karaca Z; Yılmaz M; Aktürk M; Anaforoğlu İ; Kebapçı N; Duran C; Taşlıpınar A; Kulaksızoğlu M; Gürsoy A; Dağdelen S; Erdoğan MF
    J Clin Res Pediatr Endocrinol; 2016 Mar; 8(1):13-20. PubMed ID: 26758973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC>TGG) mutation.
    Milos IN; Frank-Raue K; Wohllk N; Maia AL; Pusiol E; Patocs A; Robledo M; Biarnes J; Barontini M; Links TP; de Groot JW; Dvorakova S; Peczkowska M; Rybicki LA; Sullivan M; Raue F; Zosin I; Eng C; Neumann HP
    Endocr Relat Cancer; 2008 Dec; 15(4):1035-41. PubMed ID: 18794325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Multiple endocrine neoplasia type 2].
    Niccoli-Sire P; Conte-Devolx B
    Ann Endocrinol (Paris); 2007 Oct; 68(5):317-24. PubMed ID: 17626779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular genetics and phenomics of RET mutations: Impact on prognosis of MTC.
    Frank-Raue K; Rondot S; Raue F
    Mol Cell Endocrinol; 2010 Jun; 322(1-2):2-7. PubMed ID: 20083156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Predictive genetic investigations. Individualization of diagnosis and treatment in families with multiple endocrine neoplasia type II].
    Engelbach M; Kunt T; Kann P; Manfras B; Hankeln T; Forst T; Pfützner A; Heerdt S; Walgenbach S; Lehnert H; Beyer J
    Dtsch Med Wochenschr; 2000 Jan; 125(3):37-44. PubMed ID: 10681997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The RET gene in multiple endocrine neoplasia type 2 (MEN 2)].
    Ito T; Shirahama S; Ogura K; Yamamoto S; Takami H
    Nihon Rinsho; 2004 May; 62(5):883-8. PubMed ID: 15148813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of medullary thyroid carcinoma.
    Jiménez C; Hu MI; Gagel RF
    Endocrinol Metab Clin North Am; 2008 Jun; 37(2):481-96, x-xi. PubMed ID: 18502338
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.